Sunday, July 25, 2021
HomeLatest Pharma-NewsNovavax launches Phase III trial of Covid-19 vaccine in UK

Novavax launches Phase III trial of Covid-19 vaccine in UK

September 25, 2020: US-based biotechnology firm Novavax has started the first Phase III clinical trial of its potential Covid-19 vaccine, NVX-CoV2373, in the UK.

US-based biotechnology firm Novavax has started the first Phase III clinical trial of its potential Covid-19 vaccine, NVX-CoV2373, in the UK.

- Advertisement -

Performed in collaboration with the UK Government’s Vaccines Taskforce, the trial will investigate the safety, efficacy and immunogenicity of NVX-CoV2373.

The study is designed to recruit up to 10,000 participants aged 18 to 84 years, with and without relevant comorbidities, over the coming four to six weeks.

It is intended to involve at least 25% of subjects aged above 65 years, and also prioritise groups most impacted by Covid-19, including racial and ethnic minorities.

During the randomised, placebo-controlled, observer-blinded trial, 50% of volunteers will be given two intramuscular injections of the vaccine candidate, 21 days apart, while the remaining will receive placebo.

The vaccine dose will consist of 5µg of protein antigen and 50µg Matrix‑M adjuvant.

Novavax added that under a co-administration sub-study, up to 400 participants will also be administered with a licensed seasonal influenza vaccine.

The first primary endpoint of the Phase III trial is first occurrence of PCR-confirmed symptomatic Covid-19 with onset at least seven days following the second vaccination in subjects with no prior SARS-CoV-2 infection.”
https://www.clinicaltrialsarena.com/news/novavax-covid-vaccine-phaseiii/

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here

twenty − fifteen =

- Advertisment -

Most Popular